KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2016 - 2025)

Arbutus Biopharma's Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $11000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 96.73% year-over-year to $11000.0; the TTM value through Sep 2025 reached $352000.0, down 66.38%, while the annual FY2024 figure was $1.4 million, 1.43% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $11000.0 at Arbutus Biopharma, roughly flat from $11000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $447000.0 in Q3 2021 and bottomed at $11000.0 in Q2 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $355500.0 (2024), against an average of $332312.5.
  • The largest annual shift saw Depreciation & Amortization (CF) rose 7.58% in 2023 before it tumbled 96.91% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $427000.0 in 2021, then fell by 19.67% to $343000.0 in 2022, then rose by 7.58% to $369000.0 in 2023, then fell by 8.94% to $336000.0 in 2024, then crashed by 96.73% to $11000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Depreciation & Amortization (CF) are $11000.0 (Q3 2025), $11000.0 (Q2 2025), and $330000.0 (Q1 2025).